William Blair initiated coverage of Xencor (XNCR) with an Outperform rating. The firm believes the biopharmaceutical industry is entering a ...

Xencor's stock drops 65%, hitting all-time lows. Focus shifts to autoimmune research, but no near-term catalysts. Read why ...

Xencor (XNCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. PASADENA ...

Earnings Estimate Revisions for Xencor This biotech developing antibodies for severe autoimmune/allergic diseases and cancer is expected to earn -$3.68 per share for the fiscal year ending ...

Xencor (XNCR) closed the last trading session at $26.60, gaining 23.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall ...

Conference call with management will be held on April 16 at 2 pm hosted by JPMorgan. Webcast LinkStay Ahead of the Market: Discover ...

On March 13, 2025, the US Court of Appeals for the Federal Circuit (Federal Circuit) issued a decision titled In Re: Xencor, Inc. (the Xencor decision). The Xencor decision affirms the decision of ...

PASADENA, Calif., March 13, 2025--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today ...